The prognostic value of baseline CD4R cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting

Simple item page
dc.contributor.authorMills, Edward J.
dc.contributor.authorBakanda, Celestin
dc.contributor.authorBirungi, Josephine
dc.contributor.authorYaya, Sanni
dc.contributor.authorFord, Nathan
dc.date.accessioned2022-02-04T11:54:31Z
dc.date.available2022-02-04T11:54:31Z
dc.date.issued2012
dc.description.abstractThe risk of death is highest in the first few months after initiation of antiretroviral therapy (ART). We examined whether initial CD4þ cell count maintains a strong prognostic value among patients with at least 6 months follow-up after the initiation of ART. Design: Observational study of HIV patients in Uganda aged 14 years or older enrolled in 10 clinics across Uganda. Methods: Baseline CD4þ cell count of patients with more than 6 months of follow-up were stratified into categories (<50, 50–99, 100–149, 150–249, >250 cells/ml). A Kaplan–Meier survival analysis and Cox proportional hazards regression was used to model the associations between baseline CD4þ cell count and mortality. Results: Of 22 315 patients, 20 730 (92.8%) had more than 6 months of follow-up. Six hundred and eleven (2.9%) patients died during follow-up and 737 (3.6%) were lost to follow-up. Relative to a baseline CD4þ cell counts of less than 50 cells/ml, the adjusted hazard ratios for death were 0.83 [95% confidence interval (CI) 0.67–1.02], 0.71 (95% CI 0.57–0.88), 0.52 (95% CI 0.42–0.64), and 0.55 (95% CI 0.42–0.70) favouring those with baseline CD4þ cell counts of 50–99, 100–149, 150–249, and at least 250 cells/ml, respectively. Differing ages and male sex increased the likelihood of mortality. Conclusion: Among patients with more than 6 months of follow-up after initiation of ART, baseline CD4þ cell count at initiation still has important prognostic value. This suggests that active engagement and earlier treatment initiation is important for longterm survival.en_US
dc.identifier.citationMills, E. J., Bakanda, C., Birungi, J., Yaya, S., & Ford, N. (2012). The prognostic value of baseline CD4+ cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting. Aids, 26(11), 1425-1429. DOI:10.1097/QAD.0b013e328354bf43en_US
dc.identifier.issn0269-9370
dc.identifier.other10.1097/QAD.0b013e328354bf43
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1885
dc.language.isoenen_US
dc.publisherAidsen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectCD4þen_US
dc.subjectHIVen_US
dc.subjectPrognosisen_US
dc.subjectUgandaen_US
dc.subjectSub-Saharan Africaen_US
dc.titleThe prognostic value of baseline CD4R cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited settingen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The prognostic value of baseline CD4R cell.pdf
Size:
213.16 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences